Q1 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
1
GROWTH
Leqvio® US launch in line with expectations
Driving broad customer engagement
of prioritized
HCPs reached¹
increase in
unaided awareness²
CE Z KK LEQVIO
Establishing access and acquisition pathways
>35
of ~200 prioritized systems
have ordered Leqvio³
of corporate AIC accounts
have purchased Leqvio³
>90%
>2x
~55%
2 doses*
a year seen as
key differentiator2
>30%
of customers have
placed repeat orders³
DTC
initiated
-50%
lives have coverage
aligned to label4
Permanent J-code (J1306) has been granted and will go into effect July 1, providing greater reimbursement confidence
HCP Healthcare Professional AIC - Alternative Injection Center 1. Internal tracking. Data on file 2. Compared to Q4 2021. Based on market research. Data on file 3. Based on sales data, Data on file. 4. Internal tracking of Formal
medical policies published to date and early reimbursement experience. Data on file. *LEQVIO® is administered initially, again at 3 months, and then once every 6 months.
13 Investor Relations | Q1 2022 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation